Luke P Akard
Overview
Explore the profile of Luke P Akard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharma A, Logan B, Estrada-Merly N, Lehmann L, Rangarajan H, Preussler J, et al.
Transplant Cell Ther
. 2023 May;
29(8):523-528.
PMID: 37220838
The Center for International Blood and Marrow Transplant Research reports the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) at United States transplantation centers (TC) annually through its Center-Specific Survival Analysis...
2.
Desai P, Brown J, Gill S, Solh M, Akard L, Hsu J, et al.
J Clin Oncol
. 2021 Jun;
39(29):3261-3272.
PMID: 34156898
Purpose: Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to...
3.
LeMaistre C, Wacker K, Akard L, Al-Homsi A, Gastineau D, Godder K, et al.
Biol Blood Marrow Transplant
. 2019 Jul;
25(11):2243-2250.
PMID: 31284070
The rapid evolution of blood and marrow transplantation (BMT), coupled with diverse outcomes associated with heterogeneous groups of patients, led to the formation of 2 important organizations early in the...
4.
Pulsipher M, Logan B, Chitphakdithai P, Kiefer D, Riches M, Rizzo J, et al.
Biol Blood Marrow Transplant
. 2018 Nov;
25(4):699-711.
PMID: 30423480
The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age...
5.
Pulsipher M, Logan B, Kiefer D, Chitphakdithai P, Riches M, Rizzo J, et al.
Haematologica
. 2018 Nov;
104(4):844-854.
PMID: 30381298
Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation-related toxicities, we conducted a...
6.
Chopade P, Akard L
Clin Lymphoma Myeloma Leuk
. 2018 Aug;
18(11):710-723.
PMID: 30093283
Most patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy enables patients to experience long-term survival, with survival...
7.
Caldemeyer L, Akard L, Edwards J, Tandra A, Wagenknecht D, Dugan M
Biol Blood Marrow Transplant
. 2017 Jul;
23(11):1989-1997.
PMID: 28712934
Mixed chimerism (MC), a persistent or increasing number of host cells after allogeneic hematopoietic stem cell transplantation (HSCT), is a predictor of disease relapse. Donor lymphocyte infusions (DLI) have the...
8.
Ailawadhi S, Akard L, Miller C, Jillella A, DeAngelo D, Ericson S, et al.
Ther Adv Hematol
. 2017 Jan;
8(1):3-12.
PMID: 28042454
Background: The phase II, exploratory, open-label Exploring Nilotinib Effects (ENABL) study [ClinicalTrials.gov identifier: NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chronic...
9.
Caldemeyer L, Akard L
Leuk Lymphoma
. 2016 Aug;
57(12):2739-2751.
PMID: 27562641
With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, many patients with chronic myeloid leukemia in chronic phase (CML-CP) can expect to live near-normal life...
10.
Cortes J, Lipton J, Miller C, Busque L, Akard L, Pinilla-Ibarz J, et al.
Clin Lymphoma Myeloma Leuk
. 2016 Mar;
16(5):286-96.
PMID: 26993758
Background: Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced...